UK reg­u­la­tors green-light ear­ly ac­cess to San­thera’s Rax­one for Duchenne MD

San­thera Phar­ma­ceu­ti­cals saw its shares {SIX: $SANN} jump 16% to­day af­ter the Swiss biotech re­port­ed that UK reg­u­la­tors will pro­vide ear­ly ac­cess to their drug Rax­one (idebenone) for use in fight­ing symp­toms of Duchenne mus­cu­lar dy­s­tro­phy.

British reg­u­la­tors say that the da­ta in­di­cate that this drug can pro­vide a longterm ben­e­fit for boys ex­pe­ri­enc­ing res­pi­ra­to­ry de­cline and not on or able to take glu­co­cor­ti­coids. They al­so en­dorsed the safe­ty pro­file of the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.